TREATMENT OF ADVANCED HER2 EXPRESSING CANCER.

• 1. 通过施用抗HER2抗体-药物缀合物治疗HER2突变的癌 [P] . 中国专利： CN112153989A . 2020-12-29
• 2. 使用靶向HER2的双特异性抗原结合构建体治疗胆道癌的方法 [P] . 中国专利： CN114025795A . 2022-02-08
• 3. Treatment of advanced HER2 expressing cancer [P] . JP6914336B2 . 2021-08-04

  机译： 治疗晚期HER2表达癌症

• 4. Treatment of advanced HER2-expressing cancer [P] . KR102313262B1 . 2021-10-14

  机译： 治疗高级HER2表达癌症

• 5. TREATMENT OF ADVANCED HER2 EXPRESSING CANCER [P] . 美国专利： US2020237910A1 . 2020-07-30

  机译： 先进的HER2表达癌的治疗

• 1. Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer [J] . Huiping Li, Bin Shao, Yin Yan, 中国癌症研究（英文版） . 2016,第003期
• 2. Chidamide Combined with Paclitaxel Liposome for the Treatment of Advanced HER2-negative Breast Cancer in Clinical Study [J] . Ichrak Ben Abdallah, Mehmet Sitki Copur 现代肿瘤学研究进展(英文) . 2019,第005期
• 3. Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer. [J] . Frampton JE Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts . 2009,第15期
• 4. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. [J] . Finn RS, Press MF, Dering J Journal of Clinical Oncology . 2009,第24期
• 5. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. [J] . Capri G, Chang J, Chen SC, Annals of oncology: official journal of the European Society for Medical Oncology . 2010,第3期
• 6. An ODE model for the HER2/3-AKT signaling pathway in cancers that overexpress HER2 [C] . Itani Solomon, Gray Joe, Tomlin Claire J. 2010 American Control Conference . 2010
• 7. Bispecific Radioimmunoconjugates for Molecular Imaging and Radioimmunotherapy of HER2 Overexpressing Breast Cancer. [D] . Razumienko, Eva Joanne. 2016
• 8. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study [O] . Alberto Ocana, Marta Gil-Martin, Miguel Martín, 2017
• 9. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. [O] . Sae-Won Han, Yongjun Cha, Agnes Paquet, 2012
• 10. Ex Vivo Expansion of HER2-Specific T Cells for the Treatment of HER2- Overexpressing Breast Cancer. [R] . Knutson, K. L. 2002

• 1. Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens [J] . Olivier Dubreuil ,Aziz Zaanan ,Olivier Pellerin . 临床医学病理报告（英文） . 2015,第4期
• 2. EGFR and HER2 expression in advanced biliary tract cancer [J] . Jan Harder ,Oliver Waiz ,Florian Otto . 世界胃肠病学杂志：英文版 . 2009,第36期
• 3. CDK4/6 inhibitors in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer [J] . Xue Yang . TMR药物联合治疗 . 2020,第001期
• 4. HER2阳性晚期乳腺癌靶向治疗耐药后的治疗策略 [C] . 陆倩仪 ,王树森 . 第19届全国临床肿瘤学大会暨2016年CSCO学术年会 . 2016
• 5. 宫颈癌与转移淋巴结EGFR和HER2的表达及靶向放射治疗潜在意义 [A] . 沈俐 . 2008